Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
Time for this to show some returns | mfayman | investorshub | 09/20/2023 10:06:59 PM |
Looks pretty positive | mfayman | investorshub | 09/20/2023 9:28:58 PM |
good read | Count Crypto | investorshub | 09/20/2023 8:37:48 PM |
$OKYO The now last up | Count Crypto | investorshub | 09/20/2023 8:24:29 PM |
Looks pretty positive | Sirpeter | investorshub | 09/20/2023 7:06:11 PM |
The gaining last trade up | Sirpeter | investorshub | 09/20/2023 5:59:44 PM |
The gaining up | glenn1919 | investorshub | 09/20/2023 4:35:14 PM |
$OKYO MomentumIts gaining | mfayman | investorshub | 09/20/2023 3:48:12 PM |
what do you make of this data? | Monksdream | investorshub | 09/20/2023 3:20:49 PM |
The gaining up | Pisd | investorshub | 09/20/2023 2:43:28 PM |
The trading last trade up | Ryguy008 | investorshub | 09/20/2023 2:33:42 PM |
Price now | mfayman | investorshub | 09/20/2023 12:28:39 PM |
Lets go go go go... Up up and away we go. | Count Crypto | investorshub | 09/20/2023 11:50:34 AM |
The trading | mfayman | investorshub | 09/20/2023 10:18:37 AM |
$OKYO MomentumIts now up | mfayman | investorshub | 09/20/2023 9:45:48 AM |
$OKYO The gaining | Pisd | investorshub | 09/20/2023 9:39:30 AM |
$OKYO When is this gonna take off? | Ryguy008 | investorshub | 09/20/2023 7:40:22 AM |
$OKYO MomentumIts trading | mfayman | investorshub | 09/20/2023 6:58:40 AM |
$OKYO what does this mean? | Count Crypto | investorshub | 09/20/2023 5:32:18 AM |
MomentumIts trading last trade up | glenn1919 | investorshub | 09/20/2023 4:55:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...